Journey Medical logo

Journey MedicalNASDAQ: DERM

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 November 2021

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$109.25 M
-28%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
92%vs. sector
-22%vs. 3y high
37%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:17:26 GMT
$5.23-$0.12(-2.24%)

Dividend

No data over the past 3 years
$14.63 M$14.21 M
$14.63 M-$2.39 M

Analysts recommendations

Institutional Ownership

DERM Latest News

Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
zacks.com12 November 2024 Sentiment: NEUTRAL

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.80 per share a year ago.

Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
zacks.com04 November 2024 Sentiment: POSITIVE

Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
globenewswire.com04 November 2024 Sentiment: POSITIVE

Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T.

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
globenewswire.com25 October 2024 Sentiment: POSITIVE

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
globenewswire.com03 October 2024 Sentiment: POSITIVE

SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, scheduled to take place on Wednesday, October 9, 2024 in New York City.

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
globenewswire.com09 September 2024 Sentiment: POSITIVE

SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City.

Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript
seekingalpha.com12 August 2024 Sentiment: NEUTRAL

Journey Medical Corporation (NASDAQ:DERM ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Kalpit Patel - B. Riley Securities Scott Henry - Alliance Global Partners Jason Wittes - Roth Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
zacks.com12 August 2024 Sentiment: NEUTRAL

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
globenewswire.com12 August 2024 Sentiment: POSITIVE

New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
globenewswire.com11 July 2024 Sentiment: POSITIVE

SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors.

  • 1(current)
  • 2

What type of business is Journey Medical?

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

What sector is Journey Medical in?

Journey Medical is in the Healthcare sector

What industry is Journey Medical in?

Journey Medical is in the Drug Manufacturers - Specialty & Generic industry

What country is Journey Medical from?

Journey Medical is headquartered in United States

When did Journey Medical go public?

Journey Medical initial public offering (IPO) was on 12 November 2021

What is Journey Medical website?

https://journeymedicalcorp.com

Is Journey Medical in the S&P 500?

No, Journey Medical is not included in the S&P 500 index

Is Journey Medical in the NASDAQ 100?

No, Journey Medical is not included in the NASDAQ 100 index

Is Journey Medical in the Dow Jones?

No, Journey Medical is not included in the Dow Jones index

When was Journey Medical the previous earnings report?

No data

When does Journey Medical earnings report?

The next expected earnings date for Journey Medical is 21 March 2025